PIK3CA and PTEN Genes Expressions in Breast Cancer

Alowiri, Nabil Hadi; Hanafy, Shaden Muawia; Haleem, Reham Abdel; Abdellatif, Ahmed

doi:10.31557/apjcp.2019.20.9.2841

Cited by 10 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, from our pairwise and network meta-analysis, we found that the most effective PI3K inhibitors may be alpelisib and buparlisib. Analogous results have been obtained in some published studies [ 33 , 34 ], and the safety of the above two agents could also be tolerated.…”

Section: Discussionsupporting

confidence: 84%

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

Wang

Liu

Lian

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a promising treatment target for patients with breast cancer (BC). Our study aimed to evaluate the most effective and safe PI3K inhibitor for patients with BC, especially in PIK3CA mutation. Methods. Electronics databases were systematically searched from their inception to June 2020 for published randomized controlled trials (RCTs) comparing PI3K inhibitor therapy versus non-PI3K inhibitor therapy in patients with BC that mentioned or reported data of PIK3CA-mutated patient subgroups. Eligible RCTs had to report at least one of the following clinical outcomes: objective response rate (ORR), progression-free survival (PFS), or adverse events (AE). Results. Nine eligible RCTs involving 3872 BC patients and four PI3K inhibitor therapy arms (i.e., alpelisib, buparlisib, pictilisib, and taselisib) were included. In evaluating ORR, beneficial significant results of PI3K inhibitors could be found in the PIK3CA mutated group (1.952, 1.012 to 3.766); analogous results could also be found in 6m-PFS (1.519, 1.144 to 2.018) and PFS from HR data (-0.346, -0.525 to -0.168). From pairwise and network meta-analyses, buparlisib showed the most favorable ORR, as it was significantly different from fulvestrant in the PIK3CA-mutated patient group (2.80, 1.56 to 5.03). Alpelisib ranked first in the assessment of 6m-PFS and was significantly different from fulvestrant in the PIK3CA-mutated group (2.33, 1.45 to 3.44). The above PI3K inhibitors had good safety with few serious AEs. PROSPERO registration CRD42020193932. Conclusion. The PI3K inhibitors alpelisib and buparlisib appear to have superior efficacy and safety therapeutic choices for patients with BC, especially in PIK3CA-mutated patients.

show abstract

Section: Discussionsupporting

confidence: 84%

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

Wang

Liu

Lian

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Given the intra-tumor heterogeneity of MMR protein expression in HR+ breast cancer, the reliability and reproducibility of complementary and/or surrogate biomarkers have been investigated by several research groups. Recently, the assessment of phosphatase and tensin homolog (PTEN) expression, a key tumor suppressor gene mainly involved in DNA repair, apoptosis, and cell survival, was suggested as a complementary biomarker to pre-screen MMR status in breast cancer [ 30 , 68 ]. According to this workflow, the positive predictive value of PTEN retained status for pMMR ranged from 94.6 % in HR+ tumors to 100 % in HER2-enriched and HR − breast cancers.…”

Section: Mismatch Repair Testing: Focus On Hr+ Breast Cancermentioning

confidence: 99%

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization

et al. 2021

View full text Add to dashboard Cite

The clinical outcome of patients with a diagnosis of hormone receptor (HR)+ breast cancer has improved remarkably since the arrival of endocrine therapy. Yet, resistance to standard treatments is a major clinical challenge for breast cancer specialists and a life-threatening condition for the patients. In breast cancer, mismatch repair (MMR) status assessment has been demonstrated to be clinically relevant not only in terms of screening for inherited conditions such as Lynch syndrome, but also for prognostication, selection for immunotherapy, and early identification of therapy resistance. Peculiar traits characterize the MMR biology in HR+ breast cancers compared to other cancer types. In these tumors, MMR genetic alterations are relatively rare, occurring in ~3 % of cases. On the other hand, modifications at the protein level can be observed also in the absence of gene alterations and vice versa. In HR+ breast cancers, the prognostic role of MMR deficiency has been confirmed by several studies, but its predictive value remains a matter of controversy. The characterization of MMR status in these patients is troubled by the lack of tumor-specific guidelines and/or companion diagnostic tests. For this reason, precise identification of MMR-deficient breast cancers can be problematic. A deeper understanding of the MMR biology and clinical actionability in HR+ breast cancer may light the path to effective tumor-specific diagnostic tools. For a precise MMR status profiling, the specific strengths and limitations of the available technologies should be taken into consideration. This article aims at providing a comprehensive overview of the current state of knowledge of MMR alterations in HR+ breast cancer. The available armamentarium for MMR testing in these tumors is also examined along with possible strategies for a tailored pathological characterization.

show abstract

“…The Pik3ca gene is one of the most frequently mutated genes in breast cancer, which leads to PI3K activation (Dong et al, 2021). Recently, PI3K inhibitors can be used as a strategy for cancer treatment alone or combined with other strategies of cancer therapy (Alowiri et al 2019). Herein, treatment with Chia and Quinoa nanocapsules showed a signi cant decrease in Pik3ca expression suggesting their capability to inhibit the PI3K pathway.…”

Section: Discussionmentioning

confidence: 99%

Exploration of Tumor Growth Regression of Oil Nanocapsules via the Control of Pik3ca and Myc Expression, Anti-Inflammation and Cell Proliferation Inhibition, and Their Hepatorenal Safety in Rats

makawy,

Abdel-Aziem,

Mohammed

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The second most common cancer in the world is breast cancer. Chemotherapy is used to treat breast cancer, but instances of multidrug resistance, targets that are not selective, and physicochemical issues raise doubts about its efficacy. So, the exploration of chemopreventive agents from efficient natural sources has been required. The chia and quinoa seeds have health-promoting activities that include cardio-protective, antidiabetic, and anticancer effects. Given the paramount importance of their oils and their potential bioactivities, this work aimed to assess the repressive effect of their oils nanocapsules against mammary tumors in rats. Rat models of chemically induced mammary tumors were gavaged Chia and Quinoa nanocapsules for one month. The repressive effect of nanocapsules was studied by quantifying the TNF-α, assessing the gene expression of proto-oncogenes (Pik3ca & MYC) using qRT PCR, and analyzing the cell cycle in mammary tissue.Results The studies clarified that the inhibition of tumors in response to Quinoa and Chia nanocapsules was associated with the reduction in TNF-α levels, proliferation capability, and motivation of apoptosis. Furthermore, the Quinoa and Chia nanocapsules management repressed the activation of the MYC and Pik3ca genes. As well as nanocapsules modulated the liver enzymes and kidney function alterations induced in mammary tumor animals. Meanwhile, both oils' nanocapsules do not have an impact on the liver and kidneys of healthy rats.Conclusions The findings indicate that Quinoa and Chia nanocapsules are safe and can reduce tumor growth, suggesting a potential natural therapeutic target for breast cancer treatment.

show abstract

PIK3CA and PTEN Genes Expressions in Breast Cancer

Cited by 10 publications

References 26 publications

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization

Exploration of Tumor Growth Regression of Oil Nanocapsules via the Control of Pik3ca and Myc Expression, Anti-Inflammation and Cell Proliferation Inhibition, and Their Hepatorenal Safety in Rats

Contact Info

Product

Resources

About